Full-Time

Manager Product Lead Engineer-Owner Global Development

Technical Product Management

Posted on 9/13/2025

Deadline 9/27/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$100k - $172.5k/yr

New Hope, PA, USA + 1 more

More locations: Bridgewater Township, NJ, USA

Hybrid

Hybrid position requiring in-office presence.

Category
AI & Machine Learning (3)
, ,
Required Skills
LLM
Kubernetes
Microsoft Azure
Agile
Python
JavaScript
Neural Networks
Machine Learning
Java
Visio
Docker
.NET
AWS
JIRA
LangChain
C/C++
Linux/Unix
Snowflake
Google Cloud Platform
Requirements
  • Bachelor’s or Master’s degree in Computer Science, Engineering, Information Technology, or a related field.
  • 5+ years of proven experience in engineering with a focus on AI, generative AI, cloud computing, software engineering and automation.
  • Strong understanding of machine learning algorithms, neural networks, and AI frameworks.
  • Hands-on experience with cloud platforms such as AWS, Azure, or Google Cloud as well as experience with snowflake.
  • Proficiency in programming languages such as Python, Java, or C++.
  • Familiarity with automation tools and technologies (e.g., Kubernetes, Docker, CI/CD pipelines).
  • Excellent problem-solving skills and the ability to think strategically.
  • Analytical, curious, and eager to learn new technologies and methodologies.
  • Provide technical guidance and mentorship to junior engineers, fostering a culture of learning and innovation.
  • Ability to manage numerous projects simultaneously and meet project goals.
  • Familiarity with Linux and Windows environments and their applications in cloud solutions.
  • Experience with OpenAI APIs, LangChain, LangChat, and vector databases.
  • Excellent communication, leadership, and interpersonal skills.
  • Strong analytical and problem-solving abilities, with a focus on delivering high-quality outcomes.
  • Understanding of Agile software development methodologies and experience using JIRA for project management.
Responsibilities
  • Define the product vision, roadmap, and strategy for cloud-based solutions utilizing Generative AI technologies and associated frameworks like OpenAI APIs and LangChain.
  • Conduct market research and analyze user feedback to identify trends and requirements that inform product development decisions.
  • Lead the architectural design and implementation of scalable cloud applications on AWS or Azure.
  • Oversee the development and deployment of applications using .NET and JavaScript, ensuring coding standards and best practices.
  • Integrate LLM models to enhance application capabilities and user experiences.
  • Utilize LangGraph, LangChain and LangChat to build conversational interfaces and improve the efficiency of interactions within applications.
  • Implement vector databases for efficient data retrieval and storage, optimizing search and analytics functionalities.
  • Develop and refine prompts to maximize the efficiency and effectiveness of Generative AI models.
  • Collaborate with data scientists and machine learning engineers to enhance AI models for improved accuracy and responsiveness.
  • Work closely with cross-functional teams, including UX/UI designers, backend engineers, and data analysts, to deliver cohesive and high-quality product experiences.
  • Engage with stakeholders across the organization to gather input and ensure alignment with strategic goals.
  • Implement Agile methodologies to effectively manage the product backlog in tools like JIRA, prioritizing features based on business value and user impact.
  • Facilitate sprint planning, reviews, and retrospectives, promoting a culture of continuous improvement and collaboration.
  • Utilize Snowflake for data warehousing and analytics, ensuring effective integration and management of data across systems.
  • Design and optimize database schemas, ETL processes, and vector storage solutions to support application functionality and analytics.
  • Implement monitoring and logging solutions to track application performance, user engagement, and system health.
  • Analyze performance metrics to identify optimization opportunities and enhance user experience.
  • Ensure that all applications and cloud solutions adhere to best practices in security and compliance, safeguarding user data and organizational assets.
  • Collaborate with security teams to conduct regular audits and risk assessments.
  • Create and maintain comprehensive product documentation, including architectural diagrams and user guides, utilizing tools such as Visio where applicable.
  • Maintain clear and transparent communication with stakeholders regarding product status, challenges, and opportunities.
Desired Qualifications
  • Familiarity with CI/CD pipelines and DevOps practices.
  • Knowledge of Pharmaceutical Industry -- Clinical, Safety, Regulatory

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE